Pic

ABIOMED, Inc.

$ABMD
$381.02
Капитализция: $17B
Показать больше информации о компании

О компании

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care показать больше
to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite Impella RP, a percutaneous catheter-based axial flow pump Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite Impella RP, a percutaneous catheter-based axial flow pump Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Перевод автоматический

показать меньше

Отчетность

03.11.2021, 23:08 EPS за 3 квартал составил ХХ, консенсус YY

04.08.2021, 23:12 Прибыль на акцию за 2 квартал XX, консенсус-прогноз YY
Квартальная отчетность будет доступна после Регистрации

Прогнозы аналитиков

Аналитик Аарон Кесслер поддерживает с сильной покупкой и снижает целевую цену со xxx до yyy долларов.

25.10.2021, 16:02 Аналитик Berenberg Сунил Райгопал инициирует освещение на GoDaddy с рейтингом «Покупать» и объявляет целевую цену в xxx долларов.
Прогнозы аналитиков будут доступны после Регистрации

Все новости компании ABIOMED


14.06.2022, 23:30 МСК Abiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart Pumps DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentations from heart failure specialists, Dr. David D’Alessandro, Surgical Director, Heart Transplantation and Ventricular Assist Devices at Massachusetts General Hospital in Boston, Dr. Jane Wilcox, Chief of the Section of Heart Failure Treatment and Recovery at Northwestern Memorial Hospital in Chicago and Abiomed’s Vice President, Heart Failure, Dr. Roberta Bogaev Chapman. The presentations will provide an overview of Impella 5.5 and BTR technologies, the clinical benefit for heart failure patients and several case reviews.ABIOMED примет участие в призыве инвесторов к сердечной недостаточности благодаря сердечным насосам Impella 5.5 и Impella BTR ДЭНВЕРС, Массачусетс. — (BUSINESS WIRE) — ABIOMED, Inc. (NASDAQ: ABMD) сегодня объявила, что 24 июня 2022 г. она проведет призыв к инвесторам о возможности сердечной недостаточности с помощью насосов Impella 5.5 и будущих сердечных насосов Impella BTR. с 14:30 до 15:30 по восточному времени. На мероприятии будут представлены презентации специалистов по сердечной недостаточности, доктора Дэвида Д'Алессандро, хирургического директора отделения трансплантации сердца и вспомогательных устройств для желудочков в Массачусетской больнице общего профиля в Бостоне, доктора Джейн Уилкокс, заведующей отделением лечения и восстановления сердечной недостаточности в Северо-Западном Мемориальный госпиталь в Чикаго и вице-президент ABIOMED по сердечной недостаточности, доктор Роберта Богаев Чепмен. В презентациях будет представлен обзор технологий Impella 5.5 и BTR, клиническая польза для пациентов с сердечной недостаточностью и несколько обзоров клинических случаев.

Новости переведены автоматически

Остальные 24 новости будут доступны после Регистрации

Попробуйте все возможности сервиса Tradesense

Моментальные уведомления об измемении цен акций
Новости с официальных сайтов компаний
Отчётности компаний
События с FDA, SEC
Прогнозы аналитиков и банков
Регистрация в сервисе
Tradesense доступен на мобильных платформах